"PIQRAY (alpelisib) is a kinase inhibitor. PIQRAY film-coated tablets are supplied for oral administration with three strengths that contain 50 mg, 150 mg and 200 mg of alpelisib. The tablets also contain hypromellose, magnesium stearate, mannitol,microcrystalline cellulose, and sodium starch glycolate. The film-coating contains hypromellose, iron oxide
black, iron oxide red, macrogol/polyethylene glycol (PEG) 4000, talc, and titanium dioxide.
"
Piqray(alpelisib) Tablets: 50 mg, 150 mg, 200 mg
Recommended dosage: 300 mg (two 150 mg tablets) taken orally once daily with food. • For adverse reactions, consider dose interruption, dose reduction, or discontinuation.
PIQRAY (alpelisib) is a kinase inhibitor indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)- positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.